Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Relationship between alphaGal epitope expression and decrease of tumorigenicity in pancreatic adenocarcinoma model.

Muriel Aubert1, Christian Crotte, Liliane Benkoel

  • 1INSERM Unité 559, Faculté de Médecine, Université de la Méditerranée EA, 27 boulevard Jean Moulin, 13385 Marseille cedex 5, France.

Molecular Carcinogenesis
|March 12, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ADP-dependent platelet activation is required for thrombus formation in mice exposed to simulated flight conditions.

Blood vessels, thrombosis & hemostasis·2026
Same author

Consequences of platelet-educated cancer cells on the expression of inflammatory and metastatic glycoproteins.

PloS one·2025
Same author

The Dynamic Landscape of the Coagulome of Metastatic Malignant Melanoma.

International journal of molecular sciences·2025
Same author

Cellular and Molecular Mechanisms Leading to Air Travel-Induced Thrombosis.

Circulation research·2025
Same author

Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis.

Cancer immunology research·2024
Same author

Fitusiran reduces bleeding in factor X-deficient mice.

Blood·2024

Expressing the alphaGal epitope on pancreatic cancer cells reduced tumor growth and increased survival in animal models. This suggests alphaGal epitope expression could be a novel cancer immunotherapy strategy.

Area of Science:

  • Immunology
  • Carbohydrate Chemistry
  • Oncology

Background:

  • The alphaGal epitope (Galalpha1,3Galbeta1,4GlcNAc-R) is synthesized by alpha1,3galactosyltransferase in many mammals but not humans.
  • Human antibodies against the alphaGal epitope are implicated in xenograft hyperacute rejection.
  • The alphaGal epitope's role in hyperacute rejection suggests potential applications in cancer therapy.

Purpose of the Study:

  • To investigate if expressing the alphaGal epitope on pancreatic cancer cells can modify their tumorigenicity.
  • To evaluate the therapeutic potential of alphaGal epitope expression in a pancreatic cancer model.

Main Methods:

  • Transfection of the Syrian golden hamster pancreatic cancer cell line (HaP-T1) with the murine alpha1,3galactosyltransferase gene to express alphaGal epitopes.

Related Experiment Videos

  • Allograft transplantation of transfected and control cells into Syrian golden hamsters and nude mice.
  • Monitoring tumor development and animal survival rates.

    • Main Results:

    • AlphaGal epitope expression significantly delayed tumor development in HaP-T1 cells in vivo (2.5-fold, P < 0.05).
    • Nude mice bearing tumors expressing the alphaGal epitope showed a 100% increase in survival time.
    • Cell surface expression of the alphaGal epitope was confirmed to decrease pancreatic cancer cell tumorigenic behavior.

    Conclusions:

    • Cell surface expression of the alphaGal epitope demonstrably reduces the tumorigenic behavior of pancreatic cancer cells.
    • This finding supports the development of alphaGal epitope expression as a novel cancer gene immunotherapy strategy.